Clinical Trial Update: 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 68Ga-labeled octreotide analogue PET imaging in duodenal and pancreatic neuroendocrine tumors. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• 68Ga-labeled octreotide analogue PET tracer (68Ga-labeled octreotide analogue (e.g., DOTATATE/DOTATOC/DOTANOC))

Snippet

Sponsor: Azienda USL Reggio Emilia - IRCCS | Conditions: Neuroendocrine Tumours | Phase 2 | Status: COMPLETED